JP2009527572A - 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子 - Google Patents

免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子 Download PDF

Info

Publication number
JP2009527572A
JP2009527572A JP2008556452A JP2008556452A JP2009527572A JP 2009527572 A JP2009527572 A JP 2009527572A JP 2008556452 A JP2008556452 A JP 2008556452A JP 2008556452 A JP2008556452 A JP 2008556452A JP 2009527572 A JP2009527572 A JP 2009527572A
Authority
JP
Japan
Prior art keywords
composition
antigen
antigens
immunogenic composition
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008556452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009527572A5 (https=
Inventor
デレク ティー． オハーガン，
マンモハン シン，
ジャネット ウェンドルフ，
ジーナ カザズ，
パドマ マルヤラ，
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2009527572A publication Critical patent/JP2009527572A/ja
Publication of JP2009527572A5 publication Critical patent/JP2009527572A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2008556452A 2006-02-24 2007-02-24 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子 Withdrawn JP2009527572A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77675706P 2006-02-24 2006-02-24
PCT/US2007/004798 WO2007100699A2 (en) 2006-02-24 2007-02-24 Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013080151A Division JP2013136641A (ja) 2006-02-24 2013-04-08 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子

Publications (2)

Publication Number Publication Date
JP2009527572A true JP2009527572A (ja) 2009-07-30
JP2009527572A5 JP2009527572A5 (https=) 2011-04-14

Family

ID=38326215

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008556452A Withdrawn JP2009527572A (ja) 2006-02-24 2007-02-24 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2013080151A Pending JP2013136641A (ja) 2006-02-24 2013-04-08 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2015047973A Withdrawn JP2015110661A (ja) 2006-02-24 2015-03-11 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2016254929A Pending JP2017057227A (ja) 2006-02-24 2016-12-28 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013080151A Pending JP2013136641A (ja) 2006-02-24 2013-04-08 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2015047973A Withdrawn JP2015110661A (ja) 2006-02-24 2015-03-11 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP2016254929A Pending JP2017057227A (ja) 2006-02-24 2016-12-28 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子

Country Status (6)

Country Link
US (1) US8431160B2 (https=)
EP (1) EP1991204A2 (https=)
JP (4) JP2009527572A (https=)
AU (1) AU2007221154A1 (https=)
CA (1) CA2643322C (https=)
WO (1) WO2007100699A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518058A (ja) * 2010-01-24 2013-05-20 ノバルティス アーゲー 放射線照射された生分解性微粒子

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
EP1333858B8 (en) 2000-11-07 2006-06-14 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
WO2006081576A2 (en) 2005-01-28 2006-08-03 Galenbio, Inc. Immunologically active compositions
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
AU2013204315B2 (en) * 2007-10-19 2016-02-18 Glaxosmithkline Biologicals Sa Meningococcal vaccine formulations
WO2009050586A1 (en) * 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
EP3067048B1 (en) * 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
CA2722765C (en) * 2008-04-28 2016-10-04 Novartis Ag Nanoparticles for use in pharmaceutical compositions
ES2524699T3 (es) * 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
JP5804453B2 (ja) * 2009-05-14 2015-11-04 国立大学法人 東京大学 結晶性ポリオール微粒子及びその調製方法
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
BR112012001077A2 (pt) * 2009-07-16 2020-08-11 The General Hospital Corporation extração de ácido nucleico, métodos para avaliar a qualidade de uma extração de ácido nucleico e de uma amostra biológica, para ober ácido nucleico a partir de uma amostra biológica, para analisar rna de microvesículas e para diagnosticar e monitorar um indivíduo, e, kit
EP2475989A4 (en) 2009-09-09 2013-02-27 Gen Hospital Corp USE OF MICROVESICLES IN THE ANALYSIS OF KRAS MUTATIONS
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
US8994811B2 (en) * 2010-01-27 2015-03-31 National University Corporation Hokkaido University Diffraction microscopy
WO2011117844A2 (en) * 2010-03-26 2011-09-29 Serum Institute Of India Ltd. Method for evaluation of multiple antibodies or multiple antigens in a single sample
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX350927B (es) 2010-08-26 2017-09-26 Toray Ind Inc Star Composicion inmunogenica.
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
JP6219721B2 (ja) 2010-11-10 2017-10-25 エキソソーム ダイアグノスティックス インコーポレイテッド 核酸含有粒子の単離および該粒子からの核酸の抽出のための方法
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
US20130142878A1 (en) * 2011-12-01 2013-06-06 Flow Pharma, Inc. Peptide particle formulation
US20140105970A1 (en) * 2011-12-01 2014-04-17 Flow Pharma, Inc. Adjuvant and antigen particle formulation
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013192532A2 (en) * 2012-06-21 2013-12-27 Northwestern University Peptide conjugated particles
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US9192574B2 (en) 2013-10-24 2015-11-24 Medtronic Xomed, Inc. Chitosan paste wound dressing
US9192692B2 (en) 2013-10-24 2015-11-24 Medtronic Xomed, Inc. Chitosan stenting paste
SI3116887T1 (sl) 2014-03-13 2021-06-30 Universitaet Basel Ogljikohidratni ligandi, ki se vežejo na protitelesa img proti glikoproteinu, ki je povezan z mielinom
US11091591B2 (en) 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
WO2018025926A1 (ja) * 2016-08-04 2018-02-08 ゼノアックリソース株式会社 免疫賦活剤、医薬組成物および飲食品
TWI654993B (zh) * 2016-11-04 2019-04-01 National Health Research Institutes 陽離子型生物可降解性陶瓷聚合物微粒子用以遞送疫苗之用途
US12257294B2 (en) 2018-02-02 2025-03-25 Danmarks Tekniske Universitet Therapeutics for autoimmune disease: synthetic antigens
US11771761B2 (en) 2019-06-12 2023-10-03 Wisconsin Alumni Research Foundation Adjuvant for animal and human vaccines
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
CN111728955A (zh) * 2020-06-19 2020-10-02 中山大学 一种用于乙肝治疗的纳米颗粒及其制备方法和治疗性疫苗
US20220160822A1 (en) * 2020-11-23 2022-05-26 Wisconsin Alumni Research Foundation Neutralizing vaccines against human coronavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540077A (ja) * 1999-03-24 2002-11-26 イギリス国 ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
WO2005072088A2 (en) * 2003-12-11 2005-08-11 Sciperio, Inc. Immunotherapy compositions, method of making and method of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT991403E (pt) 1997-01-30 2003-08-29 Chiron Corp Uso de microparticulas com antigenio adsorvido para estimular respostas imunes
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6514522B2 (en) * 1998-04-08 2003-02-04 Chondros, Inc. Polymer constructs
AU763975B2 (en) 1998-07-29 2003-08-07 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbent surfaces, methods of making same, and uses thereof
GB9914412D0 (en) * 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
JP5597335B2 (ja) 1999-11-19 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 樹状細胞の微粒子ベースのトランスフェクションおよび活性化
US7838015B2 (en) 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
WO2003086454A1 (en) * 2002-04-18 2003-10-23 Akzo Nobel N.V. Antigen-loaded chitosan microparticles for oral vaccination
ATE426412T1 (de) 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
ES2434029T3 (es) 2004-11-15 2013-12-13 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas que contiene antígeno de antrax, micropartículas de polímero biodegradable, y adyuvante inmunológico que contiene polinucleótido

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540077A (ja) * 1999-03-24 2002-11-26 イギリス国 ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
WO2005072088A2 (en) * 2003-12-11 2005-08-11 Sciperio, Inc. Immunotherapy compositions, method of making and method of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518058A (ja) * 2010-01-24 2013-05-20 ノバルティス アーゲー 放射線照射された生分解性微粒子

Also Published As

Publication number Publication date
EP1991204A2 (en) 2008-11-19
US20090169636A1 (en) 2009-07-02
CA2643322A1 (en) 2007-09-07
WO2007100699A3 (en) 2008-03-13
JP2013136641A (ja) 2013-07-11
JP2015110661A (ja) 2015-06-18
AU2007221154A1 (en) 2007-09-07
CA2643322C (en) 2015-07-21
WO2007100699A2 (en) 2007-09-07
JP2017057227A (ja) 2017-03-23
US8431160B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
JP2017057227A (ja) 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
JP5806444B2 (ja) 免疫原性組成物で使用するためのナノ粒子
US10485761B2 (en) Irradiated biodegradable polymer microparticles
US9393295B2 (en) Nanoparticles for use in pharmaceutical compositions
US9517263B2 (en) Benzonaphthyridine-containing vaccines
US20110280949A1 (en) Microparticles for use in immunogenic compositions
WO2010009277A2 (en) Immunogenic amphipathic peptide compositions
JP2008525423A (ja) 糖結合体ワクチン
AU2013213717A1 (en) Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120713

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120816

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120914

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121207

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140430